Cardiovascular Diseases
The research site concentrates on cardiovascular disease investigations, enrolling participants with established disease, high cardiovascular risk, hypertension, and type 2 diabetes. Studies are designed to evaluate new drug combinations and novel peptide agents to lower the incidence of major cardiac events.
- Combination therapy with vicadrostat and empagliflozin
- Zilebesiran peptide treatment for uncontrolled hypertension
- Outcomes research in high‑risk cardiovascular populations
- Reduction of heart‑failure hospitalizations
- Interplay between metabolic disorders and cardiac risk
Ongoing work at Cvp Sociedade De Gestao Hospitalar S.A. strives to improve survival and quality of life for patients with type 2 diabetes and hypertension through innovative therapeutic strategies.
